DEF: vTv Therapeutics Inc. Announces Annual Meeting of Stockholders to be Held Virtually on June 10, 2025

vTv Therapeutics Inc. will hold its annual meeting of stockholders virtually on June 10, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Summary

• vTv Therapeutics Inc. will hold its Annual Meeting of Stockholders on June 10, 2025, at 9:00 a.m. Eastern time, as a virtual-only meeting.
• Stockholders of record as of April 15, 2025, are entitled to vote.
• The meeting's purposes include electing seven director nominees and ratifying the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting for the election of the director nominees and for the ratification of Ernst & Young LLP's appointment.
• The company is providing access to proxy materials over the Internet.
• As of April 15, 2025, there were 2,617,215 shares of Class A common stock and 577,349 shares of Class B common stock outstanding and entitled to vote at the Annual Meeting.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication, presenting necessary information for the annual meeting. The sentiment is neutral to slightly positive as it reflects routine governance processes.

Positives

• The company is embracing technology by holding a virtual-only meeting, potentially increasing accessibility for stockholders.
• The company is reducing its environmental impact and costs by providing proxy materials online.

Risks

• The IRS may challenge all or part of these tax basis increases, and a court could sustain such a challenge.
• The company's ability to achieve benefits from any tax basis increase and the payments to be made under the Tax Receivable Agreement, will depend upon a number of factors, including the timing and amount of our future income and the nature of our assets.
• To the extent that the company is unable to make payments under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue interest until paid.
• The company's organizational structure confers certain benefits upon M&F that will not benefit the holders of our Class A common stock to the same extent as it will benefit M&F.
• M&F may have different tax positions from the company, especially in light of the Tax Receivable Agreement, that could influence their decisions regarding whether and when the company should dispose of assets, whether and when the company should incur new or refinance existing indebtedness, and whether and when the company should terminate the Tax Receivable Agreement and accelerate our obligations thereunder.
• If vTv Therapeutics LLC does not distribute sufficient funds for the company to pay its operating expenses, including any payments due under the Tax Receivable Agreement, the company may have to borrow funds, which could materially adversely affect our liquidity and subject us to various restrictions imposed by any such lenders.

Future Outlook

The document outlines the agenda for the upcoming annual meeting and provides information to stockholders to facilitate informed voting decisions.

Management Comments

• The Board of Directors respectfully requests that you vote your stock in the manner described in the Proxy Statement.
• You may revoke your proxy in the manner described in the Proxy Statement at any time before it has been voted at the meeting.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions.

Comparison to Industry Standards

• The virtual-only meeting format aligns with a growing trend among companies to enhance accessibility and reduce costs.
• The director nomination process reflects standard practices, with certain investors having nomination rights based on ownership stakes.
• The compensation disclosures are consistent with SEC requirements for smaller reporting companies.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into a Tax Receivable Agreement with M&F, as successor in interest to Holdings, and M&F TTP Holdings LLC that provides for the payment by us to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that we actually realize (or, in some circumstances, we are deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of our Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by us as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
• In connection with our 2015 initial public offering, we entered into an Investor Rights Agreement with M&F, as successor in interest to Holdings.
• On February 27, 2024, the Company entered into the Securities Purchase Agreement with certain institutional accredited investors (the Purchasers).

Stakeholder Impact

• Shareholders are provided with the opportunity to vote on key company matters.
• The election of directors will shape the company's leadership and strategic direction.
• The ratification of the independent accounting firm ensures financial oversight and transparency.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 10, 2025.
• The company will announce the voting results after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Ernst & Young, Voting, vTv Therapeutics